Merck Voluntarily Discontinuing JUVISYNC™
October 07, 2013 - Merck is voluntarily discontinuing the manufacture and distribution of JUVISYNC in the United States. All products currently distributed to the market will expire by October 2014. Merck does not plan on recalling any product that has already been distributed.
This is a business decision by Merck. This decision is not based on any safety or effectiveness findings with this combination product (Sitagliptin and Simvastatin) or its individual components. The individual components of this combination product will continue to remain available. Diabetes will continue to be a priority for Merck.
JUVISYNC is used in patients for whom treatment with both Sitagliptin and Simvastatin is appropriate. Sitagliptin is prescribed with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- JUVISYNC should not be used in patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.
- The effects of JUVISYNC on patients with an increased risk of pancreatitis have not been studied.
- JUVISYNC has not been studied in conditions in which the major abnormality is elevation of chylomicrons.
- JUVISYNC is not recommended for patients with severe renal impairment or end-stage renal disease (ESRD)
because appropriate doses are not available.
Please refer to the links below for the Prescribing Information and Medication Guide for JUVISYNC: